Group 1 - The core point of the article is that Zhongheng Group reported a decline in revenue for the third quarter while showing growth in the first three quarters of the year [1] Group 2 - In the third quarter, the company's revenue was 497 million yuan, a year-on-year decrease of 3.65% [1] - The net profit for the third quarter was a loss of 2.4372 million yuan [1] - For the first three quarters, the company's revenue reached 1.948 billion yuan, reflecting a year-on-year increase of 1.10% [1] - The net profit for the first three quarters was 24.6404 million yuan, representing a year-on-year growth of 119.61% [1]

Core Viewpoint - Zhongheng Group's stock price has shown fluctuations, with a year-to-date increase of 13.82% and a recent decline over the past 20 days [1] Financial Performance - For the first half of 2025, Zhongheng Group reported revenue of 1.451 billion yuan, a year-on-year increase of 2.84%, and a net profit attributable to shareholders of 27.08 million yuan, up 23.59% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 2.941 billion yuan, with 68.74 million yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 6.05% to 114,900, while the average circulating shares per person increased by 5.14% to 28,742 shares [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with both increasing their holdings compared to the previous period [3] Market Activity - On October 24, Zhongheng Group's stock fell by 2.10%, trading at 2.80 yuan per share, with a total market capitalization of 8.947 billion yuan [1] - The stock experienced a net outflow of 468,100 yuan in principal funds, with significant buying and selling activity from large orders [1]

Core Viewpoint - Guangxi Wuzhou Zhongheng Group Co., Ltd. has successfully transformed from a traditional pharmaceutical company to a technology-driven enterprise during the "14th Five-Year Plan" period, focusing on innovation and research and development in traditional Chinese medicine and chemical drugs [1][2]. Innovation in Pharmaceuticals - Zhongheng Group has made significant strides in innovative drugs, particularly with the "Sanqi Granules," which received clinical trial approval from the National Medical Products Administration, targeting chronic kidney disease [2][3]. - The market for chronic kidney disease in China is substantial, with approximately 150 million patients and a market size exceeding 32 billion yuan, indicating a significant opportunity for the company [2]. Product Development and Brand Value - The company has been actively involved in the secondary development of core products, with the "Zhonghua Die Da Wan" being recognized as one of the "China's 500 Most Valuable Brands," valued at over 10 billion yuan [3]. - Zhongheng Group is expanding into cardiovascular disease treatments, with a new innovative drug targeting chronic heart failure, addressing a market with over 12 million patients in China [3]. Research and Development Investment - From 2021 to 2024, Zhongheng Group invested nearly 687 million yuan in R&D, accounting for 6.11% of its revenue, establishing a robust research funding mechanism [5]. - The company has formed partnerships with national key laboratories and universities to enhance its research capabilities and facilitate the transition from research to industry [5]. Smart Manufacturing and Technology Integration - Zhongheng Group has integrated modern technology into its manufacturing processes, significantly improving production efficiency, with the solid preparation workshop achieving a production rate of 1,000 pills per minute [6]. - The company holds 343 valid patents and has received multiple awards for its innovations, showcasing its commitment to modernizing traditional practices [6]. Brand Expansion and Market Reach - The company has successfully modernized its product offerings, such as the "Guilinggao," which has evolved from a traditional dessert to a health food product, now available in various convenient packaging [7][8]. - Zhongheng Group's brands have entered high-end retail markets and expanded online, contributing to a combined brand value exceeding 40 billion yuan during the "14th Five-Year Plan" [9].

Core Insights - Zhongheng Group has achieved significant milestones in the field of traditional Chinese medicine innovation, including the establishment of the "ASEAN Traditional Chinese Medicine Research Center" in collaboration with Shanghai University of Traditional Chinese Medicine, which has been recognized as a key innovation hub in Guangxi [1][2] - The company’s subsidiary, Wuzhou Pharmaceutical, has been recognized as one of the "Top 100 High-tech Enterprises in Guangxi" for two consecutive years, highlighting its innovation capabilities and industry competitiveness [1][2] Research and Development - The ASEAN Traditional Chinese Medicine Research Center focuses on key areas such as cardiovascular diseases and tumors, with a comprehensive development path that includes new drug development and secondary development of exclusive varieties [1] - Currently, 15 projects have been initiated, including three new traditional Chinese medicine drugs for treating specific conditions and one chemical drug for atopic dermatitis [1] - The center has also launched five secondary development projects for exclusive varieties, including injectable thrombolytic agents and various health products [1] Academic and Collaborative Efforts - The center has secured funding exceeding 2 million yuan through various projects, including one national key research and development project and two Guangxi natural science fund projects [2] - Collaboration with key laboratories and universities is being strengthened, with 11 experts from Shanghai University of Traditional Chinese Medicine invited to participate in projects [2] - Wuzhou Pharmaceutical has initiated over 40 research projects, including 4 national-level and 11 regional-level projects, with 25 projects successfully completed [2]

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-87 广西梧州中恒集团股份有限公司 关于政府收储控股孙公司土地的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 签订上述补充协议后，公司控股孙公司肇庆中恒制药合计收到肇庆高新区土 储中心支付的欠付款本金及利息 53,324,788.20 元。 具体内容详见公司于 2024 年 1 月 3 日、2024 年 1 月 30 日、2024 年 7 月 2 日、2024 年 10 月 9 日、2025 年 1 月 3 日、2025 年 4 月 2 日、2025 年 7 月 2 日 在上海证券交易所网站（www.sse.com.cn）披露的《广西梧州中恒集团股份有限 公司关于政府收储控股孙公司土地事项进展暨签订补充协议的公告》（公告编号： 临 2024-1）及相关进展公告（公告编号：临 2024-5、临 2024-54、临 2024-84、 临 2025-3、临 2025-34、临 2025-62）。 二、土地收储的进展情况 根据肇庆中恒制药与肇庆高新区土储中 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-86 公司已于 2025 年 8 月 30 日披露《广西梧州中恒集团股份有限公司 2025 年 半年度报告》及其摘要，为便于广大投资者更全面深入地了解公司 2025 年半年 度经营成果、财务状况，公司计划于 2025 年 10 月 17 日（星期五）10:00-11:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行互动交流。 一、说明会类型 广西梧州中恒集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 17 日（星期五）10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 10 月 10 日（星期五）至 10 月 16 日（星期四）16:00 ...

Core Viewpoint - Zhongheng Group announced that the company has no overdue guarantee matters as of September 30 [2] Company Summary - Zhongheng Group released an announcement confirming the absence of any overdue guarantee issues [2]

证券代码：600252 证券简称：中恒集团 公告编号：临2025-85 广西梧州中恒集团股份有限公司 关于为控股子公司中恒中药材提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 广西中恒中药材产业发展有限公司（以下简称 | | --- | --- | --- | --- | --- | | | | "中恒中药材"） | | | | | 本次担保金额 | 999.9852 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 3,999.9160 | | 万元（含本次担保） | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 无 | | --- | --- | | 截至本公告日上市公司及其控股子公司对外担保总额（万元） | 40,138.65 | | 对外担 ...

广西梧州中恒集团股份有限公司 收购报告书 广西梧州中恒集团股份有限公司 收购报告书 上市公司名称：广西梧州中恒集团股份有限公司 股票上市地点：上海证券交易所 股票简称：中恒集团 股票代码：600252 收购人名称：广西投资集团金融控股有限公司 住所及通讯地址：南宁市经开区星光大道 223 号 A-5-226 号 一致行动人名称：广西广投医药健康产业集团有限公司 住所地址：南宁市良庆区飞云路 6 号 GIG 国际金融资本中心 15、16 楼 通讯地址：广西南宁市江南区高岭路 100 号 签署日期：二〇二五年九月 1 广西梧州中恒集团股份有限公司 收购报告书 收购人及一致行动人声明 本声明所述的词语或简称与收购报告书"释义"部分所定义的词语或简称具有 相同的含义。 一、本报告书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 16 号— 上市公司收购报告书》及其他相关法律、法规及部门规章的有关规定编写。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》的规定，本 报告书已全面披露了收购人及其一致行动人在上市公司中拥有权益的股份变动情 ...

北京市建国门北大街 8 号华润大厦 20 层 邮编：100005 电话：(86-10) 8519-1300 传真：(86-10) 8519-1350 junhebj@junhe.com 北京市君合律师事务所 关于《广西梧州中恒集团股份有限公司收购报告书》 之法律意见书 致：广西投资集团金融控股有限公司 北京市君合律师事务所（以下简称"本所"）是在中国北京市司法局注册的律 师事务所，具备在中国从事法律服务的资格。广西投资集团有限公司（以下简称 "广投集团"或"出让人"）拟将其持有的广西梧州中恒集团股份有限公司（以下 简称"中恒集团"或"上市公司"）859,343,587 股股份（占中恒集团总股本比例 约 26.89%）对广西投资集团金融控股有限公司（以下简称"广投金控"或"收购 人"）进行增资扩股，广投金控就上述收购中恒集团股份事宜编制了《广西梧州中 恒集团股份有限公司收购报告书》（以下简称《收购报告书》）。本所根据《中华人 民共和国证券法》《中华人民共和国公司法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》《律师事 务所从事证券法律业务管理办法》及《 ...